UBS Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,244
| Closed | -$777K | – | 8972 |
|
|
2023
Q1 | $777K | Sell |
7,244
-26,610
| -79% | -$2.86M | ﹤0.01% | 3375 |
|
|
2022
Q4 | $3.72M | Buy |
33,854
+31,951
| +1,679% | +$3.51M | ﹤0.01% | 2067 |
|
|
2022
Q3 | $112K | Buy |
1,903
+1,359
| +250% | +$80K | ﹤0.01% | 4575 |
|
|
2022
Q2 | $15K | Sell |
544
-30,649
| -98% | -$845K | ﹤0.01% | 6305 |
|
|
2022
Q1 | $1.18M | Buy |
31,193
+20,284
| +186% | +$766K | ﹤0.01% | 3093 |
|
|
2021
Q4 | $431K | Buy |
10,909
+10,036
| +1,150% | +$397K | ﹤0.01% | 4094 |
|
|
2021
Q3 | $21K | Buy |
+873
| New | +$21K | ﹤0.01% | 5997 |
|
|
2021
Q2 | – | Sell |
-776
| Closed | -$14K | – | 8770 |
|
|
2021
Q1 | $14K | Buy |
+776
| New | +$14K | ﹤0.01% | 6670 |
|